You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the effect of Foundayo™ (orforglipron) on appetite?
GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Does Orforglipron Affect Appetite and Food Intake?
- Was Appetite Evaluated in Orforglipron Weight Management Trials?
- Enclosed Prescribing Information
- References
Does Orforglipron Affect Appetite and Food Intake?
Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist that binds to and activates the human GLP-1 receptor.1
Glucagon-like peptide-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.1
Orforglipron reduces body weight, with greater fat mass loss than lean mass loss. Orforglipron decreases food intake. This effect is likely mediated by decreased appetite.1
ATTAIN-1 and ATTAIN-2 were randomized, double-blind, placebo-controlled trials evaluating the efficacy and safety of orforglipron in adults with obesity or overweight. ATTAIN-1 enrolled participants without type 2 diabetes (T2D) and ATTAIN-2 enrolled participants with T2D.2,3
In ATTAIN-1 and ATTAIN-2, treatment-emergent adverse events of decreased appetite were reported in 5.8% to 8.4% and 8.2% to 15.3% of participants treated with orforglipron, respectively, compared with 3.2% and 2.9% of placebo-treated participants.2,3
These studies were conducted with an investigational orforglipron formulation at doses equivalent to the once-daily tablet dosages approved in the United States.1
Back to Content Overview.
Was Appetite Evaluated in Orforglipron Weight Management Trials?
In ATTAIN 1, the visual analog scale (VAS) was used to determine the effect of study drug on appetite and the desire for specific types of foods, while the Power of Food Scale (PFS) assessed cognitive and emotional responsiveness to food cues. Assessments were performed at week 0 (baseline) and weeks 24, 72, and 176, and post-baseline assessments were only conducted for participants with a baseline measurement.2
The appetite VAS was administered using a standardized pen and paper format consisting of eight questions evaluating
- hunger
- satiety
- fullness
- prospective food consumption, and
- desire for sweet, salty, savory, and fatty foods.2
Each item was rated on a 100 mm scale, with each end representing the extreme end of the parameter (eg, not at all hungry, extremely hungry). Participants were to mark each respective line to indicate their rating.2
For the PFS, participants rated their agreement with a series of questions on a 5-point Likert scale, ranging from 1 (do not agree at all) to 5 (strongly agree) to measure the appetite for food based on 3 levels of food proximity, namely, food available, food present, and food tasted.2
Results from ATTAIN-1 on VAS and PFS have not been published.
Back to Content Overview.
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
Date of Last Review: April 01, 2026